<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01920321</url>
  </required_header>
  <id_info>
    <org_study_id>195/12</org_study_id>
    <nct_id>NCT01920321</nct_id>
  </id_info>
  <brief_title>Bronchoscopic Thermal Saline Ablation (BTSA) of Emphysematous Lung. A New Emphysema Therapy</brief_title>
  <acronym>BTSA</acronym>
  <official_title>Lung Volume Reduction in COPD Patients With an Inhomogeneous Severe Emphysema Located in the Upper Lobes, by Injecting Warm Saline Through the Bronchoscope Channel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim: To evaluate feasibility, safety and efficacy of relatively simple approach of
      bronchoscopic lung volume reduction (LVR) technology, independent of collateral ventilation.

      Description: Patients with severe upper lobes heterogeneous emphysema, undergo unilateral
      bronchoscopic installation of saline thermal energy 50-55 ºC intending to induce an
      inflammatory airway and parenchymal injury and consequently fibrotic response resulting in
      LVR;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion criteria:

        1. Age 40-75 unlimited sex. 20 subjects

        2. chronic obstructive pulmonary disease (COPD), GOLD 3-4 (global obstructive lung
           disease).

        3. CT scan of lung and included high resolution slices. Demonstrating emphysematous,
           bullotic changes in the upper lobes.

        4. Pulmonary function tests results- total lung capacity(TLC)&gt;110%, residual
           volume(RV)&gt;150%, diffusion of lung CO(DLCO)&lt;80%,forced expiratory volume 1
           second(FEV1):15-45%.

        5. 6 minute walking distance (6MWD)&gt; 140 meters.

      Exclusion criteria:

        1. Active ischemic heart disease, significant arrhythmia. ejection fraction (EF) &lt;40%.

        2. COPD that cause carbon bioxide(CO2) retention above 50 mm Hg and / or oxygen saturation
           at rest below 88%.

        3. Pulmonary hypertension&gt; 45 mmHg, according to the Echo Test.

        4. . Cancer treatment with chemotherapy / radiation or expected life expectancy of less
           than two years.5. Pregnancy.

      Methods: . A. Patient preparation and sedation as in diagnostic bronchoscopy. Sedation will
      be based on midzoln + demerol. The patients will be treated prior the treatment with
      Inhalation with salbutamol ans ipratropium bromide. Flexible bronchoscope with outer diameter
      5 mm is introduced to the targated upper lobe, and placed in wedged position. This is
      followed by installion of 0.9% natriu, chloride(NaCl) at a temperature of 55ºC exit
      temperature 50ºC) in portions of 40 ml to 200 ml (in bronchoalveolar lavage up to 300 ml is
      acceptable. The patient is placed in horizontal position, and continuous ECG blood pressure.
      Oxygen saturation are monitored. This monitoring will be continue at least 2 hours after
      treatment. A chest x-ray is followed and the patient remain in the department for overnight.

      Tracking: Minimum of 6 months - Outpatient follow up include in addition to physical
      examination extended pulmonary function test and after 3-6 months. low radiation chest CT.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary function improvemnt</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical - COPD assessment test (CAT ) + lung volumes + diffusion capaciry and 6MWD .</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Emphysema</condition>
  <arm_group>
    <arm_group_label>Endoscopic lung volume reduction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After usual sedation, bronchoscope is introduce to the lung and palced in segmental wedge position then hot salineis instilled. Same procedure to others affected segments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic lung volume reduction</intervention_name>
    <description>Prior the procedure patients undergo - high resolution chest CT , extensive phisiological assessment.</description>
    <arm_group_label>Endoscopic lung volume reduction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 40-75 unlimited sex. 20 subjects

          2. COPD, GOLD 3-4 (global obstructive lung disease).

          3. CT scan of lung and included high resolution slices. Demonstrating emphysematous,
             bullotic changes in the upper lobes.

          4. Pulmonary function tests results- TLC&gt; 110%, RV&gt; 150%, DLCO &lt;80%,FEV1: 15-45%.

          5. 6 minute walking distance &gt; 140 meters.

        Exclusion Criteria:

          1. Active ischemic heart disease, significant arrhythmia. Ejection fraction (EF) &lt;40%.

          2. Chronic lung disease that cause CO2 retention above 50 mm Hg and / or oxygen
             saturation at rest below 88%.

          3. Pulmonary hypertension&gt; 45 mmHg, according to the Echo Test.

          4. . Cancer treatment with chemotherapy / radiation or expected life expectancy of less
             than two years.

          5. Pregnancy -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>david Stav, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assaf-Harofeh Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Stav, MD</last_name>
    <phone>972- 89779024</phone>
    <email>dstav@asaf.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isaac Shpirer, MD</last_name>
    <phone>972- 89779024</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Center</name>
      <address>
        <city>Beer Yaakov</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Stav, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2013</study_first_submitted>
  <study_first_submitted_qc>August 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2013</study_first_posted>
  <last_update_submitted>August 8, 2013</last_update_submitted>
  <last_update_submitted_qc>August 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Bronchoscopic LVR</keyword>
  <keyword>Emphysema</keyword>
  <keyword>Hot injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

